Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.66 |
| ▸ | FNTA | P49354 | 6/20 | 0.54 |
| ▸ | FNTB | P49356 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768047 | 1.00 | TACR1 (0.66) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL6903041 | 1.00 | TACR1 (0.66) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8545840 | 0.91 | TACR1 (0.67) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956909 | 0.91 | TACR1 (0.67) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8548669 | 0.87 | TACR1 (0.64) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956927 | 0.87 | TACR1 (0.64) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956845 | 0.86 | TACR1 (0.68) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8957044 | 0.86 | TACR1 (0.68) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8957083 | 0.86 | TACR1 (0.68) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956821 | 0.84 | TACR1 (0.61) | TACR1FNTAFNTBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1079863-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LTD. (GB) | 2001-03-07 | — | — | EP | claimed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| EP-0799056-B1 | USE OF A NK-1 RECEPTOR ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME (GB) | 2002-03-27 | — | — | EP | disclosed |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MERCK & CO., INC. | 2002-03-21 | — | — | US | disclosed |
| US-6180624-B1 | BY ADMINISTERING A COMBINATION OF A MORPHOLINE OR THIOMORPHOLINE TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LIMITED (GB) | 2001-01-30 | — | — | US | disclosed |
| US-6162805-A | Use of an NK-1 receptor antagonist and an SSRI for treating obesity | MERCK SHARP & DOHME LIMITED (GB) | 2000-12-19 | — | — | US | disclosed |
| US-6090819-A | Use of NK-1 receptor antagonists for treating mania | MERCK SHARP & DOHME, LTD. (GB) | 2000-07-18 | — | — | US | disclosed |
| EP-0799056-A1 | USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LTD. (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996020009-A1 | USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MTNR1A, PROKR1, NTSR2 | TACR1 45/4885FNTA 4439/4885FNTB 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.